ClinicalTrials.gg
RecruitingNCT06237153Updated Feb 1, 2024

Randomized Placebo Controlled Study of Triamcinolone Acetonide Extended Release Injection for Thumb (CMC) Osteoarthritis

A Phase 2 interventional study of Triamcinolone Acetonide extended release suspension in Carpometacarpal (CMC) Osteoarthritis, sponsored by Marie Badalamente. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Marie Badalamente · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing Triamcinolone Acetonide in Osteoarthritis — 1 open to participants now, 2 under way, 1 of them phase 3. Triamcinolone Acetonide · Osteoarthritis.

Planned enrollment
14th of 19
30 · median 70
Started
2023
the only one that year
Phase 2
12 of 19
1 open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
Marie Badalamente

Among the 19 studies testing Triamcinolone Acetonide in Osteoarthritis, this one is the 14th largest by planned enrollment, is the only one that started in 2023, is one of 12 in phase 2, and was the 18th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

1 of the 19 studies testing Triamcinolone Acetonide in Osteoarthritis is open now, in 1 country.

By country, each count listing its studies:

About Triamcinolone Acetonide

Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Triamcinolone Acetonide in Osteoarthritis, or all of them as a file.
02

Study summary

The goal of this study is to investigate if a timed release steroid injection may be beneficial in treating carpometacarpal (CMC) joint (thumb) osteoarthritis. The main questions to be answered are:

  1. does the steroid injection substantially reduce pain in the thumb
  2. does the steroid injection help to increase thumb function Participants will be asked to undergo a thumb CMC joint injection and to attend follow up visits to assess pain and thumb function.
Read the detailed description

Current Orthopaedic practice for CMC osteoarthritis involves prescribing thumb braces, oral non steroidal anti inflammatory medications (NSAID's) and/or corticosteroid injection(s) which may provide minimal relief, until symptoms become unbearable, leading to difficult and often complex surgical intervention and extended and painful post operative recovery times. Addition of a safe and effective and longer lasting conservative intervention may decrease pain and increase function in patients affected by CMC osteoarthritis.

Triamcinolone acetonide extended-release (TA-ER) suspension is novel and composed of polylactic-co-glycolic acid microspheres which allows for timed release of the steroid over the course of 12 weeks. It is FDA approved as Zilretta for injection and treatment of osteoarthritis of the knee.

We hypothesize that in a randomized, placebo controlled, double blind study that patients having TA-ER injection to the CMC joint will exhibit decreased pain levels and increased thumb function based on grip, tip and pinch strengths compared to placebo patients. One group of patients will receive CMC joint TA-ER injection and the other saline CMC joint injection. All will be followed for 12 weeks and one longer term follow up visit at 180 days.

Triamcinolone acetonide extended-release (steroid) injection for carpometacarpal (CMC) joint osteoarthritis may provide improved pain relief and thumb function as a conservative treatment for osteoarthritis of the base of the thumb.

03

Conditions studied

  • Carpometacarpal (CMC) Osteoarthritis

Browse trials for

Keywords

  • Thumb Osteoarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female > 18 years of age.
  2. X ray diagnosis of CMC osteoarthritis Eaton stages I, II or III.
  3. VAS pain score in affected thumb of 5 or greater.
  4. Written obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
  5. Willing to abstain from use of the following protocol-restricted medications during the study to be kept in a log if non compliant.

    • Opioid or over the counter medications for pain for the study duration

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant or nursing or plan to become pregnant during the study; women who plan to conceive during the study; or unwilling to practice during participation in the study.
  2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  3. Known or suspected to TA-ER (or component of TA-ER), triamcinolone acetonide.
  4. Stage IV CMC osteoarthritis is excluded. Rationale for exclusion of stage IV is that these patients are most likely surgical candidates due to severe joint damage. Other exclusion criteria include rheumatoid arthritis, septic or gouty arthritis or psoriatic arthritis, thumb joint effusion, DeQuervain's disease, trigger thumb or history of CMC joint surgical reconstruction, or terminal or chronic and serious, uncontrolled associated medical conditions. Patients who have received hyaluronan or rich plasma (PRP) injections to the affected CMC joint within 6 months will be excluded. Patients who have received a injection to the affected CMC joint within 3 months will be excluded.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Triamcinolone acetonide extended release suspension injection

    Active drug treatment

    Drug: Triamcinolone Acetonide extended release suspension

  • Placebo comparator
    Saline Placebo Injection

    Placebo comparator

    Drug: Triamcinolone Acetonide extended release suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Visual Analog Pain Score

    PAIN

    Time frame: Day 1 of injection to six months post injection

Secondary outcomes

  1. QuickDash Thumb Function Questionnaire

    Thumb Function

    Time frame: Day 1 of injection to six months post injection

  2. Grip Strength

    Grip Strength

    Time frame: Day 1 of injection to six months post injection

  3. Pinch Strength

    Pinch Strength

    Time frame: Day 1 of injection to six months post injection

  4. Key Strength

    Key Strength

    Time frame: Day 1 of injection to six months post injection

07

Study locations

1 of 1 sites recruiting
  • Stony Brook Orthopaedics
    Stony Brook, New York 11794, United States
    Recruiting
    • Susan Greco · ContactSusan.Greco@stonybrookmedicine.edu · 631-444-3421
    • Marie Badalamente, PhD · Principal investigator
    • Samantha I. Muhlrad, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2025, 25 months after the start.

Of 82 phase 2 interventional studies under Osteoarthritis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 1, 2024
StartActual
Nov 21, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06237153
Lead sponsor
Marie Badalamente
Responsible party
Marie Badalamente (Professor, Stony Brook University) — Sponsor-investigator
First posted
Feb 1, 2024
Start date
Nov 21, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 1, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion